Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Epcoritamab demonstrates efficacy in CAR T-naïve B-cell lymphoma patients, with 61% overall response and 45% complete response rates. Median progression-free survival and overall survival were ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma. Among patients with relapsed/refractory diffuse large B-cell ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...

Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

The FDA issued a complete response letter for glofitamab-gxbm plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), citing insufficient STARGLO trial ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) ...